Search

Displaying results 221 - 230 of 4188 in total
  1. Drug

    Bethanidine

    go.drugbank.com/drugs/DB00217
    Approved

    A guanidinium antihypertensive agent that acts by blocking adrenergic transmission.

  2. Drug

    Latanoprost

    go.drugbank.com/drugs/DB00654
    ApprovedInvestigational

    [A184493] It has been found to be well-tolerated and its use does not normally result in systemic adverse effects like other drugs used to treat elevated intraocular pressure, such as [Timolol].

  3. Drug

    Sodium tartrate

    go.drugbank.com/drugs/DB13707
    ApprovedWithdrawn

    It acts as an emulsifier and pH control agent in food products [L2590].

  4. Drug

    Phenylpropanolamine

    go.drugbank.com/drugs/DB00397
    ApprovedVet approvedWithdrawn

    Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. … It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.

  5. Drug

    Antrafenine

    go.drugbank.com/drugs/DB01419
    Approved

    It is not widely used as it has largely been replaced by newer drugs. … Antrafenine is a piperazine derivative drug that acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen.

  6. Drug

    Eptinezumab

    go.drugbank.com/drugs/DB14040
    ApprovedInvestigational

    [L12318] Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP).

    Categories: Calcitonin Gene-related Peptide Antagonist, Calcitonin Gene-Related Peptide (CGRP) Antagonists
  7. Drug

    Timolol

    go.drugbank.com/drugs/DB00373
    ApprovedInvestigational

    [L6724] This drug is marketed by several manufacturers [L6736] and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.

  8. Drug

    Levobetaxolol

    go.drugbank.com/drugs/DB09351
    Approved

    It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.

  9. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    [L56065] Navepegritide was approved by the US FDA in February 2026 for use in patients 2 years of age and older with achondroplasia with open epiphyses.[L56058,L56065]

  10. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    [L49266] It was approved alongside [exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based gene therapies for the treatment of SCD in patients … Lovotibeglogene autotemcel consists of autologous hematopoietic stem and progenitor cells transduced with the BB305 lentiviral vector encoding a modified β-globin gene.

    Categories: Autologous Hematopoietic Stem Cell-Based Gene Therapy